Ianalumab

From WikiMD's Wellness Encyclopedia

Ianalumab is a human monoclonal antibody designed for the treatment of diseases that are mediated by the B cell activating factor (BAFF), such as systemic lupus erythematosus and Sjögren's syndrome. It was developed by Novartis.

Mechanism of action[edit | edit source]

Ianalumab works by binding to the B cell activating factor (BAFF), a protein that plays a key role in the survival and proliferation of B cells. By blocking BAFF, ianalumab reduces the number of B cells, which are thought to contribute to the development of autoimmune diseases.

Clinical trials[edit | edit source]

Ianalumab has been tested in several clinical trials. In a phase II trial for systemic lupus erythematosus, ianalumab showed a significant reduction in disease activity compared to placebo. A phase III trial is currently underway.

Side effects[edit | edit source]

The most common side effects of ianalumab include infections, headache, and nausea. Serious side effects can include severe infections and allergic reactions.

See also[edit | edit source]

References[edit | edit source]


Ianalumab Resources
Wikipedia


WikiMD
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD

WikiMD's Wellness Encyclopedia

Let Food Be Thy Medicine
Medicine Thy Food - Hippocrates

WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Prab R. Tumpati, MD